IMPORTANT- We are requiring all individuals that enter our clinic to wear a properly fitting face mask.
We are now accepting payments online through our patient portal.
Click on the title to see the full article:
The Nail Psoriasis Severity Index (napsi) 13 years later: validation of an instrument to assess psoriatic nail involvement
The Nail Psoriasis Severity Index (NAPSI): Validation of an Instrument to Assess Psoriatic Nail Involvement
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3. randomized, placebo-controlled trial
The Nail Psoriasis Severity Index (NAPSI) 12 years later: Validation of an instrument to assess psoriatic nail involvement and a review of its use and controversy
Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3
Adalimumab for Nail Psoriasis: Efficacy and Safety from the First 26 Weeks of a Phase-3, Randomized, Placebo-Controlled Trial
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year
How To Choose My Treatment
Improvement in nail psoriasis in the open-label extension of a phase-2 trial of ixekizumab in patients with moderate-to-severe plaque psoriasis
Ixekizumab treatment improves nail psoriasis in patients with moderate-to-severe psoriasis results from the randomized and controlled as well as open-label phases of UNCOVER-3
Nail Psoriasis
The modified Nail Psoriasis Severity Index validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis
Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1
Currently Recruiting Studies:
Adult Eczema (Atopic Dermatitis)
Pediatric Eczema (2 to 17 years of age)
Psoriasis (2 and over)
Nail Psoriasis (18 and over)
Call our new research patient line to see if you qualify! (503) 222 - SKIN